254.21 USD
+27.06
11.91%
At close Jul 30, 4:00 PM EDT
After hours
254.21
+0.00
0.00%
1 day
11.91%
5 days
8.90%
1 month
-0.94%
3 months
-13.19%
6 months
-5.50%
Year to date
5.93%
1 year
46.87%
5 years
13.22%
10 years
515.52%
 

About: Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.

Employees: 4,500

0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

502% more call options, than puts

Call options by funds: $95.8M | Put options by funds: $15.9M

138% more first-time investments, than exits

New positions opened: 93 | Existing positions closed: 39

50% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2024] → 6 (+2) [Q1 2025]

13% more funds holding

Funds holding: 367 [Q4 2024] → 416 (+49) [Q1 2025]

11% more capital invested

Capital invested by funds: $8.3B [Q4 2024] → $9.24B (+$946M) [Q1 2025]

9% more repeat investments, than reductions

Existing positions increased: 141 | Existing positions reduced: 129

1.27% less ownership

Funds ownership: 90.97% [Q4 2024] → 89.7% (-1.27%) [Q1 2025]

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$285
12%
upside
Avg. target
$311
23%
upside
High target
$350
38%
upside

7 analyst ratings

positive
86%
neutral
14%
negative
0%
Truist Securities
David Rescott
22%upside
$310
Buy
Maintained
30 Jul 2025
UBS
Priya Sachdeva
32%upside
$335
Buy
Maintained
30 Jul 2025
RBC Capital
Shagun Singh
28%upside
$325
Outperform
Maintained
30 Jul 2025
Baird
David Rescott
12%upside
$285
Outperform
Maintained
30 Jul 2025
Wells Fargo
Larry Biegelsen
14%upside
$290
Overweight
Maintained
30 Jul 2025

Financial journalist opinion

Based on 12 articles about PEN published over the past 30 days

Neutral
PRNewsWire
3 hours ago
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference
ALAMEDA, Calif. , July 30, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025.
Penumbra, Inc. to Present at the Canaccord Genuity 45th Annual Growth Conference
Positive
The Motley Fool
3 hours ago
Penumbra (PEN) Q2 Revenue Jumps 13%
Penumbra (PEN) Q2 Revenue Jumps 13%
Penumbra (PEN) Q2 Revenue Jumps 13%
Neutral
Seeking Alpha
22 hours ago
Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript
Penumbra, Inc. (NYSE:PEN ) Q2 2025 Earnings Conference Call July 29, 2025 4:30 PM ET Company Participants Adam Elsesser - Co-Founder, Chairman, President & CEO Cecilia Furlong - Corporate Participant Jason Richard Mills - Executive Vice President of Strategy Maggie S. Yuen - Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair & Company L.L.C.
Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 day ago
Penumbra (PEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Penumbra (PEN) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Penumbra (PEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Positive
Zacks Investment Research
1 day ago
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates
Penumbra (PEN) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.64 per share a year ago.
Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates
Neutral
PRNewsWire
1 day ago
Penumbra, Inc. Reports Second Quarter 2025 Financial Results
ALAMEDA, Calif. , July 29, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2025.
Penumbra, Inc. Reports Second Quarter 2025 Financial Results
Neutral
Zacks Investment Research
1 day ago
ITGR vs. PEN: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Penumbra (PEN). But which of these two stocks is more attractive to value investors?
ITGR vs. PEN: Which Stock Is the Better Value Option?
Positive
Zacks Investment Research
6 days ago
Will Penumbra (PEN) Beat Estimates Again in Its Next Earnings Report?
Penumbra (PEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Penumbra (PEN) Beat Estimates Again in Its Next Earnings Report?
Negative
Reuters
1 week ago
Five years after COVID, pharma shares languish in US policy limbo
Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies since Donald Trump returned to the White House.
Five years after COVID, pharma shares languish in US policy limbo
Positive
Zacks Investment Research
1 week ago
Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth
Penumbra (PEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Penumbra (PEN) Reports Next Week: Wall Street Expects Earnings Growth
Charts implemented using Lightweight Charts™